Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

Pricing
Back to journals
Academic Journal

Journal of Substance Abuse Treatment

2 Papers Indexed in Blossom

Published Papers

Paywallmeta

A systematic literature review of clinical trials and therapeutic applications of ibogaine

This systematic review (2021) explores clinical trials involving ibogaine and noribogaine. Across the number of trials included, a total of 705 individuals were treated with either ibogaine or noribogaine. It was found that such interventions may be useful for treating substance use disorders, alleviating withdrawal symptoms and cravings. Importantly, a number of severe side effects, including death, that have been recorded in the trials are discussed.

Published
July 1, 2022
Journal
Journal of Substance Abuse Treatment
Authors
Köck, P., Frölich, K., Walter, M., Lang, U., Dürsteler, K. M., Köck, P.
Open Accessindividual

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up

This randomised double-blind clinical trial (2002, n=70) found that existential psychotherapy in combination with psychedelic doses of intramuscular (im) ketamine (140mg/70kg) achieved larger results in the treatment of heroin addiction than sub-hallucinogenic doses (14mg/70kg).

Published
December 1, 2002
Journal
Journal of Substance Abuse Treatment
Authors
Krupitsky, E. M., Burakov, A. M., Romanova, T. N., Dunaevsky, I. V., Strassman, R. J., Grinenko, A. Y.

Quick Facts

Papers Indexed
2
Publisher
Elsevier
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.